TOP TEN perturbations for 3493 (Homo sapiens)

Organism: Homo sapiens
Gene: 3493
Selected probe(set): 217022_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 3493 (217022_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

collecting duct carcinoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):8.843561
Number of Samples:2 / 2
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

MEDI-551 study 3 (3 mg/kg) / scleroderma study 4 (placebo; 85d)

Relative Expression (log2-ratio):-7.6008368
Number of Samples:3 / 4
Experimental MEDI-551 study 3 (3 mg/kg)
Whole blood samples from adult scleroderma patients 85 days after a single intravenous injection of MEDI-551 (3 mg/kg), an anti-CD19 monoclonal antibody. ATC code:---
Control scleroderma study 4 (placebo; 85d)
Whole blood samples from adult scleroderma patients 85 days after a single intravenous placebo treatment. ATC code:---

colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)

Relative Expression (log2-ratio):-7.018676
Number of Samples:2 / 5
Experimental colorectal cancer study 43 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma.
Control colorectal cancer study 43 (metastase; lung)
Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma.

MEDI-551 study 3 (10 mg/kg) / scleroderma study 4 (placebo; 85d)

Relative Expression (log2-ratio):-6.9409437
Number of Samples:6 / 4
Experimental MEDI-551 study 3 (10 mg/kg)
Whole blood samples from adult scleroderma patients 85 days after a single intravenous injection of MEDI-551 (10 mg/kg), an anti-CD19 monoclonal antibody. ATC code:---
Control scleroderma study 4 (placebo; 85d)
Whole blood samples from adult scleroderma patients 85 days after a single intravenous placebo treatment. ATC code:---

rheumatoid arthritis study 1 / normal synovial membrane tissue

Relative Expression (log2-ratio):6.8647757
Number of Samples:5 / 6
Experimental rheumatoid arthritis study 1
Synovial membrane tissue from patients with rheumatoid arthritis.
Control normal synovial membrane tissue
Normal synovial membrane tissue.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):6.8539486
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):6.6088924
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

inclusion body myositis study 1 / normal biceps tissue

Relative Expression (log2-ratio):6.569028
Number of Samples:5 / 3
Experimental inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).
Control normal biceps tissue
Biceps femoris biopsy muscle samples from control subjects.

Barrett's esophagus study 3 / esophageal squamous cell carcinoma study 1

Relative Expression (log2-ratio):6.1175213
Number of Samples:17 / 8
Experimental Barrett's esophagus study 3
Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection.
Control esophageal squamous cell carcinoma study 1
Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy.

immune cell study 10 (IgG memory B-cell) / immune cell study 10 (naive B-cell)

Relative Expression (log2-ratio):6.1099434
Number of Samples:5 / 5
Experimental immune cell study 10 (IgG memory B-cell)
Class switched IgG memory B-cells (IgG+CD27+) isolated from peripheral blood of healthy adult donors (between 25 and 60 years of age). Mononuclear cells were isolated by Ficoll?Paque density centrifugation and CD19+ B-cells were enriched by magnetic cell separation using the MACS system or by negative selection using the EasySep Human B-Cell Enrichment Kit. B-cell suspensions were stained with anti-CD27 APC, anti-IgD PE?Cy7, anti-IgM FITC, and anti-IgG PE or anti-CD21 PE antibodies and sorted with a FACSDiva cell sorter as class switched IgG memory B-cells.
Control immune cell study 10 (naive B-cell)
Naive B-cells (IgM+IgD+CD27-) isolated from peripheral blood of healthy adult donors (between 25 and 60 years of age). Mononuclear cells were isolated by Ficoll?Paque density centrifugation and CD19+ B-cells were enriched by magnetic cell separation using the MACS system or by negative selection using the EasySep Human B-Cell Enrichment Kit. B-cell suspensions were stained with anti-CD27 APC, anti-IgD PE?Cy7, anti-IgM FITC, and anti-IgG PE or anti-CD21 PE antibodies and sorted with a FACSDiva cell sorter as naive B cells.